OREX institutional ownership is now 91.5% and growing (see FMR's SC 13G/A filed Aug 24).
I guess that's why there's not much retail discussion on that board.
Why is ARNA in such a hurry to get Bel-Phen approved when it will also have a black label warning?
And ARNA can't wait for their (Bel-Phen) black box version to be FDA approved?
But why pay .05 for $5 call when $4.50 call is .05 ask and $3.50 call is .10?
Insiders may have info to be released after today's close?
Options actually expire 11:59 am tomorrow.
Let's hold for this options close and hope for some OREX news next week.
Pending contract potential not relying on outcome of expensive, time consuming
clinical trials. ARNA at 52 week low today betting on the far off future. I want them to
recover and stop dragging OREX down. Get over there and do some pumping!
It wasn't my point, but your response brings up another point. It looks like the shorts (over 25% of the float)
are currently the ones controlling the PPS.
VVUS 66.89%, ARNA 57.97%
Who was the only one with a decreased institutional position?
ALISO VIEJO, Calif., Aug. 11, 2015 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced that a panel of the U.S. Court of Appeals for the Federal Circuit has upheld the validity and enforceability of Avanir's patents covering NUEDEXTA (U.S. Patent Nos. 7,659,282 (the '282' patent) and 8,227,484 (the '484' patent)). The decision confirms patent protection for NUEDEXTA until 2026 in the United States.
The Appeals Court ruling affirmed the April 2014 decision upholding the '282' and '484' patents' validity by the U.S. District Court for the District of Delaware in a lawsuit brought by Avanir against the generic manufacturers Par Pharmaceuticals, Inc. and Impax Laboratories, Inc.
Last Friday 7-24-2015:
OREX up 9.69%.
ARNA down 2.41%.
Whole market down more than 1%.
OREX must have some good news for this August 6 business update.
With all your posts, you must be worried.
What's tomorrow to bring?
Think about it!
Please show your source.
The only lawsuit is see is:
Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® Patents
SAN DIEGO, June 5, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that it and its North American partner, Takeda Pharmaceuticals, have filed a lawsuit in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis.
The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Contrave® (naltrexone HCl / bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Takeda and Orexigen filed the lawsuit on the basis that Actavis' proposed generic products infringe each of these patents.
In accordance with the Hatch-Waxman Act, as a result of having filed a lawsuit within 45 days of the Paragraph IV certification notice, FDA approval of the ANDA will be stayed until the earlier of (i) 30 months from Takeda's receipt of the notice or (ii) a District Court decision finding that the identified patents are invalid, unenforceable or not infringed.
Orexigen and Takeda plan to vigorously enforce Contrave intellectual property rights.